Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis ...Middle East

PR Newswire - News
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis
BARCELONA, Spain, May 21, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the regulatory approval of...

Hence then, the article about almirall receives positive chmp opinion for klisyri tirbanibulin an innovative topical treatment for actinic keratosis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News